Clinical Trial Update: Anti-CD20 Radioimmunotherapy Before Chemotherapy and Stem Cell Transplant in Treating Patients With High-Risk B-Cell Malignancies [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating anti-CD20 radioimmunotherapy before chemotherapy and stem cell transplant in high-risk B-cell malignancies; trial status is terminated …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Non-hodgkin Lymphoma
• Burkitt Lymphoma
• Diffuse Large B-cell Lymphoma
• Indolent Non-hodgkin Lymphoma
• Mantle Cell Lymphoma
• Mature B-cell Non-hodgkin Lymphoma

Drugs mentioned

• Anti-CD20 radioimmunotherapy

Snippet

Sponsor: Fred Hutchinson Cancer Center | Conditions: Burkitt Lymphoma, CD20-Positive Neoplastic Cells Present | Phase 1 | Status: TERMINATED | Results posted: 2020-11-23